Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia

Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Barth, Brian M., Wang, Weiyuan, Toran, Paul T., Fox, Todd E., Annageldiyev, Charyguly, Ondrasik, Regina M., Keasey, Nicole R., Brown, Timothy J., Devine, Viola G., Sullivan, Emily C., Cote, Andrea L., Papakotsi, Vasiliki, Tan, Su-Fern, Shanmugavelandy, Sriram S., Deering, Tye G., Needle, David B., Stern, Stephan T., Zhu, Junjia, Liao, Jason, Viny, Aaron D., Feith, David J., Levine, Ross L., Wang, Hong-Gang, Loughran, Thomas P., Sharma, Arati, Kester, Mark, Claxton, David F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737412/
https://ncbi.nlm.nih.gov/pubmed/31488436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018021295
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados